Sight Sciences (NASDAQ: SGHT) net income
Sight Sciences reported a net loss of $38.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $51.5m. Earnings per share were −$0.74.
Sight Sciences's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$38.4m | — | −49.7% | −$0.74 |
| 2024 | −$51.5m | — | −64.5% | −$1.03 |
| 2023 | −$55.5m | — | −68.5% | −$1.14 |
| 2022 | −$86.2m | — | −120.9% | −$1.80 |
| 2021 | −$63.0m | — | −128.6% | −$2.36 |
| 2020 | −$34.7m | — | −125.5% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sight Sciences net income compared with its sector
By net income for its latest fiscal year, Sight Sciences ranks 235th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Sight Sciences, −49.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 233rd | Sanara Medtech | −$37.6m | −36.4% |
| 234th | Candel Therapeutics | −$38.2m | — |
| 235th | Sight Sciences | −$38.4m | −49.7% |
| 236th | Monte Rosa Therapeutics | −$38.6m | −31.2% |
| 237th | Lifecore Biomedical | −$38.7m | −30.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Sight Sciences
- How much did Sight Sciences earn in fiscal 2025?
- Sight Sciences reported a net loss of $38.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $51.5m.
- What are the earnings per share of Sight Sciences?
- They were −$0.74 in fiscal 2025, compared with −$1.03 in fiscal 2024.
- Where does Sight Sciences rank in its sector by net income?
- It ranks 235th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Sight Sciences come from?
- From the annual report (Form 10-K) that Sight Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sight Sciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Sight Sciences: the Sight Sciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.